Global Breast Cancer Screening Market revenue is set to rise from US$ 7,461.8 million in 2022 to US$ 16,340.5 million by 2031, growing at a CAGR of 9.1% During the Forecast Period From 2023 to 2031.
Due to its increasing frequency and the potential for catastrophic results if not detected early, breast cancer continues to be a significant problem for global health. Due to factors like increased awareness, improvements in screening technology, and government measures to support early diagnosis, the need for breast cancer screening has been steadily rising in recent years.
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/breast-cancer-screening-market
The rising incidence of breast cancer will cause the market to grow throughout the forecast period. Breastcancer.org estimates that there were 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer in the United States in 2022. Due to the rising demand for breast cancer screening tests in both developed and emerging nations, the market is likely to grow throughout the projected period. There are regional variations in the prevalence of breast cancer, with some locations having greater incidence rates. With over 40% of all new cases worldwide, Asia is the region most affected by breast cancer.
The advantages of early screening are being actively promoted by governments, healthcare institutions, and advocacy groups in today’s breast cancer awareness campaigns. These programs seek to enhance women’s involvement in screening programs by educating them about the value of routine mammography and clinical breast examinations. For instance, in October 2023, the Estée Lauder Companies will reprise their yearly campaign during Breast Cancer Awareness Month. The Estée Lauder Companies are launching several new campaigns this month as part of their ongoing efforts to fight breast cancer. These campaigns are intended to raise money for research, continue their efforts to educate the public, and raise awareness of a disease that will claim 685,000 lives worldwide in 2020 and be diagnosed in 2.3 million people.
Diagnostics Center Contributed Over 35% of Market Revenue Share
The main end user in the global market is the segment of diagnostic centers. In 2022, the segment contributed the highest revenue share of 35% and is likely to grow at a compound annual growth rate (CAGR) of 9.2% during the forecast period.
One of the primary factors supporting the establishment of diagnostic facilities is the increasing need for early detection and consultation among patients with breast cancer. Diagnostic facilities are a useful and easily available option for patients, especially in urban areas, due to their accessibility. Many diagnostic centers now participate in breast cancer awareness campaigns, partnering with charities to enhance screening programs and educate the public on the need for early detection.
North America to Generated About 33% of Market Revenue Share
Due to its advanced healthcare system and large breast cancer research initiatives, North America dominated the global breast cancer screening market. The region’s ability to generate revenue is likely to have improved from its present level of over 31% market share to over 32.6% by 2031.
In the competitive healthcare market, North America stands out as a model of innovation and achievement. Its commanding position in the global battle against breast cancer is backed by its significant research programs, first-rate medical facilities, and sizeable market share.
In the US, cancer is the second biggest killer. As a result, there has been a significant rise in revenue for breast cancer screening in this country. The American Cancer Society predicts that in the US alone, 1.9 million new cancer cases were diagnosed, and 609,360 people died from cancer in 2022. That works out to a shocking daily average of around 1,670 fatalities.
The United States National Breast Cancer Foundation (NBCF) announced funding of more than US$ 12.4 million for 20 research initiatives in May 2022. The NBCF’s stated objective is to achieve “zero fatalities from breast cancer” by 2030. It is projected that initiatives to reduce breast cancer will stimulate market growth in the region.
Additionally, the region’s free breast cancer screening clinics and awareness efforts are anticipated to fuel market expansion throughout the course of the projection year. For instance, in October 2022, Pennsylvania Hospital collaborated with the American Cancer Society, the Consulate of Mexico in Philadelphia, and Univision 65 to hold a yearly breast cancer screening event, offering free mammograms to women without insurance or with inadequate insurance in the Philadelphia neighborhood.
For the full report, please follow this link- https://www.astuteanalytica.com/industry-report/breast-cancer-screening-market
List of Prominent Companies Profiled
- Siemens Healthcare
- Hologic, Inc
- Myriad Genetics
- Metabolomic Technologies Inc
- Biocrates Lifesciences AG
- A&G Pharmaceuticals
- Provista Diagnostics Inc
- Roche Diagnostics
- Lineage Cell Therapeutics, Inc. (Biotime Inc.)
- General Electric Company
- Quest Diagnostics
- Agendia NV
- Oncocyte Corporation
- Allengers Medical Systems Ltd.
- Other Prominent Players
The global breast cancer screening market segmentation focuses on Test Type, End User, and Region.
By Test Type
- Imaging Tests
- Film mammography
- Digital mammography
- Digital breast tomosynthesis (DBT)
- Genetic Tests
- Other screening Tests (Breast Exam, Thermography, Tissue sampling)
By End User
- Research Labs
- Cancer Institutes
- Diagnostics Centers
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Western Europe
- Asia Pacific
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
The request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/breast-cancer-screening-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/